Identification of a claudin-4 and E-cadherin score to predict prognosis in breast cancer by Szász, Attila Marcell et al.
Identification of a claudin-4 and E-cadherin score to
predict prognosis in breast cancer
Attila M. Szasz,1 Zsuzsanna Nemeth,1 Balazs Gyorffy,2 Mariann Micsinai,3,4 Tibor Krenacs,5 Zsolt Baranyai,6
Laszlo Harsanyi,7 Andras Kiss,1 Zsuzsa Schaff,1 Anna-Maria Tokes1 and Janina Kulka1,8
1Second Department of Pathology, Semmelweis University, Budapest; 2Research Laboratory of Pediatrics and Nephrology, Hungarian Academy of Sciences,
Budapest, Hungary; 3Center for Health Informatics and Bioinformatics, New York, New York; 4Department of Pathology and Yale Cancer Center, New
Haven, Connecticut, USA; 5First Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest; 6Department of Surgery
and Vascular Surgery, Uzsoki Memorial Hospital, Budapest; 7First Department of Surgery, Semmelweis University, Budapest, Hungary
(Received June 15, 2011 ⁄ Revised August 8, 2011; August 16, 2011 ⁄ Accepted August 22, 2011 ⁄ Accepted manuscript online August 29, 2011)8To whom correspondence should be addressed. E-mail: kj@korb2.sote.huThe elevated expression of claudins (CLDN) and E-cadherin (CDH-1)
was found to correlate with poor prognostic features. Our aim
was to perform a comprehensive analysis to assess their potential
to predict prognosis in breast cancer. The expression of CLDN-1,
-3–5, -7, -8, -10, -15, -18, and E-cadherin at the mRNA level was
evaluated in correlation with survival in datasets containing
expression measurements of 1809 breast cancer patients. The
breast cancer tissues of 197 patients were evaluated with tissue
microarray technique and immunohistochemical method for
CLDN-1–5, -7, and E-cadherin protein expression. An additional val-
idation set of 387 patients was used to test the accuracy of the
resulting prognostic score. Based on the bioinformatic screening
of publicly-available datasets, the metagene of CLDN-3, -4, -7, and
E-cadherin was shown to have the most powerful predictive
power in the survival analyses. An immunohistochemical protein
profile consisting of CLDN-2, -4, and E-cadherin was able to predict
outcome in the most effective manner in the training set. Combin-
ing the overlapping members of the above two methods resulted
in the claudin-4 and E-cadherin score (CURIO), which was able to
accurately predict relapse-free survival in the validation cohort
(P = 0.029). The multivariate analysis, including clinicopathological
variables and the CURIO, showed that the latter kept its predictive
power (P = 0.040). Furthermore, the CURIO was able to further
refine prognosis, separating good versus poor prognosis sub-
groups in luminal A, luminal B, and triple-negative breast cancer
intrinsic subtypes. In breast cancer, the CURIO provides additional
prognostic information besides the routinely utilized diagnostic
approaches and factors. (Cancer Sci, doi: 10.1111/j.1349-7006.
2011.02085.x, 2011)
I nvestigation of the expression of tight junction molecules hasrecently gained increased importance due to its implicated
prognostic value in breast cancer.(1,2) The recently-identified
new subtypes, named ‘‘claudin-low’’ breast carcinomas, pro-
pose a new challenge for the breast cancer research community
due to their rarity. This subgroup typically exhibits high histo-
logical grade, with stem cell and epithelial-to-mesenchymal
transition features, low expression of cell–cell junction proteins,
and probably poor response to systemic therapy.(3,4)
E-cadherin (CDH-1), a transmembrane protein that functions
in epithelial cell–cell interactions as part of adherent junctions, is
linking the membrane to the cytoskeletal matrix through inter-
actions with a- and b-catenin. It is used in routine diagnostic
pathology to distinguish lobular and ductal carcinomas.(5) Studies
evaluating the expression of E-cadherin report the loss of these
molecules in approximately 80% of lobular carcinomas.(6–10)
Claudin (CLDN) tight junction molecules were originally
described by Furuse et al. in 1998.(11) In the past decade, there
have been multiple attempts to evaluate their expression in
several pathological states and organs.(12) In 36 of 39 invasivedoi: 10.1111/j.1349-7006.2011.02085.x
ª 2011 Japanese Cancer Associationbreast cancer samples that we reported on in an earlier study,
there was either an absence or scattered presence of the CLDN-
1 protein.(13) Claudin-1 expression also correlated with recur-
rence status and malignant potential in another study.(14) A
decreased level of CLDN-4 expression was observed in the
majority of grade 1 invasive ductal carcinomas (IDC).(15) Fur-
thermore, CLDN-4 expression was significantly higher in basal-
like breast carcinomas.(16) The loss of CLDN-7 was found to
correlate with histological grade in both ductal carcinoma in situ
and IDC, and its expression was lost in the majority of lobular
carcinoma in situ cases.(17) The reduced expression of CLDN-7
correlated not only with higher tumor grade, but also with the
metastatic states, including loco-regional recurrences.(18)
Reduced CLDN-16 expression was also described in metastatic
breast tumors.(19)
Alterations in intercellular junctions and membrane proteins
might lie behind some morphological and invasive properties of
carcinomas. The changes of E-cadherin, CLDN-1, -4, and -7
expressions with their prognostic value and the recently-estab-
lished intrinsic claudin-low subtype together underline the
importance of the role of tight junction molecules in neoplastic
transformation and the prognosis of breast cancer. Therefore, a
systematic analysis of junctional protein families (CLDN and
also cadherins) might be of prominent relevance. In the present
study, we identified tight junction family molecules capable of
acting as prognostic biomarkers in breast cancer.
Materials and Methods
Breast cancer datasets. An in silico analysis of publicly-avail-
able microarray data from 13 datasets was performed in the first
line.(20–32) The refined and established database was based
on the gene expression data (Affymetrix human genome unigene
[HGU]133A and HGU133 + 2 microarrays only), and survival
information of 1809 patients downloaded from gene expression
omnibus (GEO) (Table 1).(33) The expression data of CDH-1,
CLDN-1, -3–11, and -14–18 were analyzed. All available probes
were used for the analysis, excluding those that were not reliable
across datasets (average expression <100, and maximal expres-
sion <500 of micro array suite [MAS]-5-normalized value). The
signature containing the average score for all of the abovemen-
tioned CLDN and E-cadherin expression data was assigned as
the complex junctional signature (CJS).
Breast cancer samples. The study was approved by the Insti-
tutional Review Board of Semmelweis University (Budapest,
Hungary).
A training cohort of 197 selected breast carcinomas diagnosed
between 1982 and 2007 with known relapse, and cases
with no recurrence of disease on long-term follow-up, wasCancer Sci | 2011
Table 1. Clinicopathological characteristics of the patients and tumor samples used in the study
Cohort Datasets Training Validation
Patients n 1809 197 387
Age Years ± SD 57 ± 13 60 ± 15 59 ± 13
Follow-up time Months ± SD 123 ± 82 111 ± 12 102 ± 9
Relapse events n (%) 689 (38.1%) 97 (49.2%) 153 (39.5%)
Histological type IDC 0 118 (47.3%) 165 (65.8%)
ILC 0 77 (30.9%) 27 (15.4%)
Other 0 54 (21.6%) 46 (18.6%)
Unknown 1809 0 0
Grade 1 98 (5.4%) 56 (22.4%) 181 (22.4%)
2 534 (29.5%) 122 (48.9%) 145 (48.9%)
3 312 (17.2%) 71 (28.5%) 91 (28.5%)
Unknown 865 (52.1%) 0 0
Subtype ER positive 968 (53.5%) 139 (70.5%) 319 (82.4%)
ER negative 578 (31.9%) 58 (29.4%) 67 (17.3%)
Unknown 263 (14.5%) 0 0
ER, estrogen receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; SD, standard deviation.set up (Table 1). Selected cases of formalin-fixed and
paraffin-embedded (FFPE) tissues underwent histological
re-examination, and regions of interests were marked for core
punching. According to the diagnostic reports, which interpreted
the immunophenotype as a surrogate of the molecular subtype,
there were 98 luminal A, 41 luminal B, 20 HER-2-positive, and
38 triple-negative breast cancer (TNBC) tumors (Fig. S1).
The expression of CLDN-1–5, -7, and E-cadherin proteins were
evaluated by immunohistochemistry (IHC).
The validation cohort consisted of 387 unselected breast can-
cer samples diagnosed between 1999 and 2002 (Table 1). Of
these, 148 (38.2%) received anthracycline- or taxane-based che-
motherapy, and 101 additionally received irradiation (68.2%).
Of the remaining 239 patients undergoing surgical resection
without chemotherapy, 112 (46.8%) received radiotherapy.
Recurrence-free survival curves according to histological type,
grade, and molecular subtype are shown in Figure S1. The sam-
ples were analyzed for CLDN-4 and E-cadherin protein expres-
sion in the same fashion as the training set.
The tumors were previously classified during routine patho-
logical examination into luminal A (estrogen receptor [ER]- and
progesterone receptor [PgR]-expressing tumors with <20% Ki67
index and epidermal growth factor receptor-2 [HER-2] negativ-
ity), luminal B (ER- or PgR- and HER-2-expressing tumors, and
ER- and PgR-expressing carcinomas with more than 20% Ki67
index), HER-2 (ER- and PgR-negative and HER-2 expression of
3+ at IHC or amplified by FISH evaluation when the IHC score
was 2+), and TNBC (no expression of ER, PgR, or HER-2, nor
amplification of the latter with FISH) groups.(34)
Tissue microarray construction. Tissue microarray construc-
tions (TMA) of all FFPE tumors were composed with the TMA
builder instrument (Histopathology, Pe´cs, Hungary). The cores
were 2 mm, in diameter and all the samples were investigated in
duplicates.
Immunohistochemistry. The IHC reactions were performed
on 4 lm-thick sections obtained from the TMA blocks. After
deparaffinization, the slides were heated in a microwave oven in
target retrieval solution (DAKO, Carpinteria, CA, USA) for
30 min. The automated Ventana ES immunostainer system was
used according to the protocol provided by the manufacturer
(Ventana Medical Systems, Tucson, AZ, USA). The E-cadherin
and CLDN antibodies were used as follows: CLDN-1 (cat. no.
18-7362; Zymed, South San Francisco, CA, USA) at 1:80, )2
(cat. no. 18-7363; Zymed) at 1:80, )3 (cat. no. 34-1700; Zymed)
at 1:80, )4 (cat. no. 18-7341; Zymed) at 1:100, )5 (cat. no. 18-
7364; Zymed) at 1:120; )7 (cat. no. 34-9100; Zymed) at 1:100,2and E-cadherin (cat. no. M3612; DAKO) at 1:100. The tissues
were counterstained with Mayer’s hemalaun (00-8011; Zymed).
Positive controls and negative control tissues were applied in all
IHC runs.
Immunohistochemistry evaluation. The immunohistochemical
reactions were considered positive when the CLDN (except
CLDN-2, which was granular cytoplasmic, predominantly sub-
membranous) and E-cadherin were expressed at the cell mem-
branes (Fig. S2). Claudin-5 was not only expressed in the tumor
cells, but in the endothelial cells as well. The stained slides were
digitalized with a slide scanner (Mirax Scan; 3DHistech, Buda-
pest, Hungary), and the intensity of the reaction (0, negative
reaction; +1, weak positivity; +2, moderate positivity; and +3,
strong reaction) and the frequency of positive cells (1, 0–5%; 2,
>5–10%; 3, >10–20%; 4, >20–33%; 5, >33–50%; 6, >50–66%;
7, >66–80%; and 8, >80–100%) were integrated into a scoring
system using TMA module software (version 11.49; 3DHistech)
resulting in a numerical variable (range: 0–11) consisting of the
sum of the intensity and frequency scores above. The indices
were created from the arithmetic means of the respective CLDN
and E-cadherin.
Statistics. The analyses for the datasets were performed in
the R statistical environment (R version 2.10.1; R Foundation
for Statistical Computing, Vienna, Austria) using the prediction
analysis of microarrays (PAM) (version 2.19; Stanford Univer-
sity Labs, Stanford, CA, USA).(35) The PAM uses soft threshold-
ing to produce a shrunken centroid, which allows the selection
of genes with high predictive potential. This made it possible to
derive the simplified junctional signature (SJS) from the CJS,
including all investigated mRNA transcripts. The data analysis
and the statistical evaluation of tissue samples were performed
with the SPSS 15.0 Family Pack (SPSS, Chicago, IL, USA). In
the training cohort, all proteins were included in the first analy-
sis testing the complex junctional profile (CJP). The latter score
was reached when considering all scores of all proteins, and tak-
ing their arithmetic average as a numerical variable. All individ-
ual values of the distinct scores of IHC were included in the
statistical evaluation. The Mann–Whitney U-test was performed
for non-parametric statistical analyses. Hierarchical clustering
was used to rank the protein expression data according to their
contribution to the identification of prognostic groups. Similar
to the gene expression signature, this helped to define those pro-
teins (simplified junctional profile [SJP]) that were able to define
the prognostic subgroups by themselves. Combining the over-
lapping members of the gene and protein expression methods
resulted in the claudin-4 and e-cadherin score (CURIO), whichdoi: 10.1111/j.1349-7006.2011.02085.x
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was tested to predict survival in the validation cohort. The con-
tribution of expression data to predict relapse-free survival
(RFS), distant metastasis-free survival (DMFS), and overall
survival (OS) was displayed according to the Kaplan–Meier
method, and statistically supported with log–rank test. For the
multivariate analysis, the Cox regression method was applied.
P-values of <0.05 were considered to be statistically significant.
Results
Claudin and E-cadherin mRNA expression in the public dataset-
based training set. First, a CJS was used, including the average
expression of the following genes: CDH-1, CLDN-1, -3–11, and
-14–18 (Fig. 1a). The predictive value of the CJS was significant
in all the prognostic estimate aspects (P ⁄RFS ⁄ = 2.4E-07,
P ⁄DMFS ⁄ = 0.0064, and P ⁄OS ⁄ = 0.00041).Fig. 1. (a) Kaplan–Meier curve showing the distinguished groups
according to expression of the complex junctional signature in the
datasets. (b) Curve showing the distinguished groups according to the
expression of the simplified junctional signature in the datasets. ( )
Gene_expression = 0, ( ) gene_expression = 1.
Szasz et al.To further refine our analysis, the top genes were ranked
based on their centroid plots (displaying the contribution of
genes to the definition of prognostic subgroups in order of their
strength), resulting in a more powerful predictive capacity for
outcome. Based on the average expression of CDH-1, CLDN-3,
-4, and -7, this SJS has performed as follows (P ⁄RFS ⁄ = 5.1E-
10, P ⁄DMFS ⁄ = 0.00041, and P ⁄OS ⁄ = 0.00018). The elevated
expression (median <) of mRNA resulted in poor outcomes, as
compared to the lower expression (< median) of this signature
(Fig. 1b). Of note, these genes have the best estimated quality of
the probe set (average expression >500 MAS-5-normalized
value), as compared to other CLDN genes.
The database rendered feasible to test the SJS signature in the
ER-positive and ER-negative patient cohorts separately. The
SJS signature was predictive for DMFS in the ER-positive group
(P = 0.043), especially in the ER-positive, lymph node (LN)-
negative subgroup (P = 0.010). When considering ER-negative
cancers, the SJS performed even better; it was able to predict
RFS and DMFS in the ER-negative group (P ⁄RFS ⁄ = 0.0037
and P ⁄DMFS ⁄ = 0.0052), and even in the ER-negative,
LN-negative subgroup (P ⁄RFS ⁄ = 0.0087; P ⁄DMFS ⁄ = 0.013).
The sample number was too low for meaningful analysis in the
ER-negative, LN-positive group (Fig. S3).
Expression of CLDN proteins in breast cancer intrinsic subtypes
in our tissue-based training set. The expression of E-cadherin
and the CLDN-1–5 and -7 proteins was examined in breast car-
cinomas, according to previously-defined subtypes. The expres-
sion of CLDN-1 was lowest in the luminal B subtype, and
CLDN-4 was less expressed in luminal A cancers. E-cadherin
showed the highest expression among HER-2+ tumors (Fig. 2).
There was no single marker distinguishing TNBC from other
subgroups (Fig. 3).
Claudin proteins distinguish prognostic groups in the training
set of breast cancers based on IHC. In line with bioinformatics,
we investigated the expression of E-cadherin and the CLDN-1–
5 and -7 proteins in our breast carcinoma cases to test their rele-
vance as prognostic factors. All scores of the evaluated proteins
were included in the index signature (CJP), reflecting the aver-
age of all individual expression values. Groups were created at
the median level of the combined scores (P = 0.006; Fig. 4a).
In the next step, the CJP was investigated for its main drivers.
The proteins were ranked according to their contribution to theFig. 2. Expression of claudin-1–5, -7, and E-cadherin in subtypes of
breast cancer, and expression of claudins in intrinsic breast cancer
subtypes luminal-1. HER-2, human epidermal growth factor receptor-
2; TNBC, triple-negative breast cancer. ( ) Claudin-1, ( ) claudin-2, ( )
claudin-3, ( ) claudin-4, ( ) claudin-5, ( ) claudin-7, ( ) E-cadherin.
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Fig. 3. Expression of claudins in intrinsic breast cancer subtypes Luminal A and B 2. Significance levels of comparison based on the
Mann–Whitney U-test of the expressed claudins between the breast cancer subtypes. HER-2, human epidermal growth factor receptor-2; TNBC,
triple-negative breast cancer.CJP with hierarchical clustering (Fig. S4). The analysis revealed
that the CLDN-2, -4, and E-cadherin protein expressions aver-
aged were able to distinguish between poor versus good prog-
nostic groups with similar confidence as the CJP, resulting in an
SJP (P = 0.007). All components were able to distinguish prog-
nostic subgroups by themselves (Fig. S5), but none performed
as good as the SJP (Fig. 4b).
Identification and validation of CURIO based on correlation to
survival in an independent cohort. We were able to select the
SJS in silico based on the combined mRNA expression of CDH-
1, CLDN-3, -4, and -7 for a robust prediction of outcome. This
overlaps with the training cohort-defined protein expression-
based SJP consisting of CLDN-2, -4, and E-cadherin. Thus, we
aimed to validate the score-designated CURIO in an indepen-
dent cohort of 387 patients.
Separated at the median, the CURIO was able to show stron-
ger predictive power for RFS (hazard ratio [HR] = 1.51, 95%
confidence interval [CI]: 1.04–2.19, P = 0.029; Fig. 5) than the
expression of CLDN-4 and E-cadherin individually (HR = 1.43,
95% CI: 1.02–2.03, P = 0.038, and HR = 1.39, 95% CI: 1.01–
1.90, P = 0.039, respectively).
Next, the treatment data were correlated to CURIO. None of
the chemotherapy or radiotherapy data showed a correlation
with CURIO based on the chi-square test (Pearson’s v2-test:
0.822, P = 0.191; Pearson’s v2-test: 5.124, P = 0.346, respec-
tively). To support this, the treatment groups underwent further
analysis: tumors with no treatment following surgery, either
radiotherapy or chemotherapy, or both radiotherapy or chemo-
therapy following surgical removal of the tumor, were sepa-
rately tested for impact of the CURIO on prognosis. All the
treatment groups showed the expected trend, although they did
not turn out to be significant in either comparison (Fig. S6).
Cox multivariate regression analysis was performed, consider-
ing the CURIO, grade, vascular invasion, necrosis, lymph node4status, and subtype. In the pretest, the CURIO was correlated with
tumor size (P = 0.040), histological type (P = 0.001), and Not-
tingham Prognostic Index (NPI) (P = 0.004) with v2-test analy-
sis, thus these variables were omitted from the Cox multivariate
regression test. The CURIO, vascular invasion, and intrinsic sub-
type kept their predictive power after this analysis (Table 2).
Performance of CURIO in the distinct intrinsic subtypes of the
validation cohort. The CURIO was predictive for prognosis in
luminal A breast tumors, showing the expected distribution of
high expression, that is, worse prognosis (P = 0.006). In luminal
B tumors, the trend was opposite: the higher expression value of
the CURIO resulted in a better outcome, as compared to the
lower expression split at the median again (Fig. 6), but the result
was not significant (P = 0.198).
In the ER-negative subtypes, the CURIO did not provide any
information on the outcome of HER-2-positive tumors
(P = 0.547), while in TNBC, the same effect was seen as in
the majority of cases; the lower CURIO value resulted in better
outcome measures (P = 0.047).
Discussion
In the present study, we identified a signature (SJS) based on the
expression of selected CLDN and E-cadherin in datasets con-
taining mRNA expression data of 1809 breast cancer patients.(33)
In a separate cohort of 197 patients using protein expression on
TMA, we identified a similar index (SJP) overlapping with SJS.
Regarding the defined signature at the mRNA level, CLDN-3,
-4, -7, and E-cadherin have been identified by others at the same
time as the present study was conducted,(1,4) emphasizing the
role of these molecules’ expression in the prognosis of breast
cancer. One has to note that these genes have the best estimated
quality of the probe set, as compared to the CLDN genes, thus
the selection might has technical origin.doi: 10.1111/j.1349-7006.2011.02085.x
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Fig. 4. (a) Kaplan–Meier curve showing the distinguished groups
according to expression of the complex junctional profile in the tissue
samples. (b) Curve showing the distinguished groups according to
expression of the simplified junctional profile in the tissue samples.
( ) Low (< median), ( ) high (< median).
Fig. 5. (a) Kaplan–Meier curve showing the distinguished groups
according to expression of the claudin-4 and E-cadherin score in the
tissue samples. (b) Kaplan–Meier estimates of E-cadherin on relapse-
free survival. (c) Kaplan–Meier graph of claudin-4 expression predictive
of relapse-free survival. ( ) Low (< median), ( ) high (< median).
Table 2. Results of the Cox multivariate analysis with hazard ratios
(HR) and 95% confidence intervals (CI)
Parameter P-value HR
95% CI
Lower Upper
CURIO 0.040 1.503 1.02 2.216
Subtype 0.001 1.064 0.59 1.918
Vascular invasion 0.011 0.704 0.31 1.808
Lymph node mets 0.091 0.791 0.6 1.038
Grade 0.767 1.037 0.82 1.32
Necrosis 0.232 2.233 0.72 8.435
CURIO, claudin-4 and E-cadherin score.The SJS was able to predict DMSF and its predictive power,
even improved in ER-positive lymph node negative tumors. In
the ER-negative group, the signature provided almost the same
performance, predicting RFS and showing DMFS tendency. The
same was true for the ER-negative, LN-negative cancers,
although the lower number of ER-negative tumors did not make
a complete analysis feasible. Therefore, analyses in an even lar-
ger dataset are needed, because most HER-2-positive and TNBC
tumors had high expression of these molecules in this analysis,
which in the majority of cases, results in poor prognosis. Also
regarding claudin-low tumors, a significantly larger number of
patients need to be investigated in depth for CLDN tumor
expression. Recent studies also focus on ER-negative carcino-
mas to define their prognosis and to predict their response to
treatment. Human epidermal growth factor receptor-2 amplified
breast cancer has become the representative of targeted cancer
therapy.(36) The results showed that triple-negative carcinomasSzasz et al.show the best response to chemotherapeutical agents(37) and
came into focus in search of tailored therapeutic approaches
(platinum agents and poly[ADP-ribose] polymerase [PARP]
inhibitors) and diagnostic key markers (e.g. CLDN).(1,38,39)
In tissue-based investigations, there is a frequent discrepancy
between reports regarding CLDN expression.(15–18,40) In this
analysis, we investigated the expression of CLDN and E-cadher-
in for breast cancer intrinsic subtypes. In 197 cases representing
all subtypes reflected by IHC characterization, CLDN-1 was
expressed predominantly in luminal A tumors, while CLDN-4
and E-cadherin tended to be expressed in ER-negative (HER-2
and TNBC) tumors at a higher level. The TNBC tumors seem to
form a heterogenous group, according to CLDN expression. In
our training cohort, we found that CLDN-2, -4, and E-cadherin
expressions were the most powerful profile to predict the time of
RFS, which was similar to earlier studies.
The CURIO, the combination of CLDN-4 and E-cadherin,
was predictive for prognosis in general, according to high
expression, that is, worse prognosis, and lower expression,
resulting in a better outcome, especially in luminal A cases.
Additionally, TNBC might not only be heterogeneous according
to the CLDN expression, but there is a group among the luminal
tumors that might show the characteristics of claudin-low
tumors. This might shed light on a previously described sub-
group of luminal tumors, which did not detach themselves in
repeated observations,(41) and shared features with triple-nega-
tive and HER-2-amplified breast tumors.(42) In HER-2-positive
tumors, the CURIO did not provide any information on out-
come, while in TNBC, surprisingly, the same effect was seen as
in the majority of cases; a lower CURIO resulted in better out-
come measures. Thus, we suggest that with the addition ofCancer Sci | 2011 | 5
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Fig. 6. Kaplan–Meier curve showing the prognostic groups according to the expression of the claudin-4 and E-cadherin score in the luminal A
(a), luminal B (b), human epidermal growth factor receptor-2 (HER-2) (c), and triple-negative breast cancer (d) subtypes. ( ) Low (< median),
( ) high (< median).CLDN-4 and E-cadherin IHC, the prognosis of breast cancer
can be further refined in the routine setting.
There are two major advances of the CURIO over the vari-
ables (grade, vascular invasion, necrosis, lymph node status,
and subtype). First, these variables depend on the pathologi-
cal examination of the tissue, second, their examination is
less objective than the CURIO.(43) Evaluation of IHC is semi-
quantitative; therefore, we position the CURIO in between
the interobserver variable clinicopathological classifiers and
the microarray ⁄ PCR-based, more objective tests, especially
for those practices with limited resources.
As chemotherapeutical and radiotherapeutic treatment data
were available, the CURIO was also tested in treatment groups.
Although this comparison could show that the score might be
prognostic in all the different treated cohorts, a study with a
larger number of patients needs to evaluate this question; this is
a limitation of the study.
Numerous parameters were implicated in the prediction of
breast cancer prognosis. We slowly start to understand that the
picture is extensively complicated: a certain factor and its rela-
tion to a biological function and prognosis can only be used
under certain circumstances (e.g. different prognostic informa-6tion according to intrinsic subtype of breast cancer). The classi-
fication of tumors based on expression signatures and marker
profiles can help us to understand the diversity of neoplastic
disease and change a paradigm in our concept regarding breast
cancer.
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